Emerald Therapeutics, Inc.

United States of America

Back to Profile

1-8 of 8 for Emerald Therapeutics, Inc. Sort by
Query
Patent
Aggregations Reset Report
Jurisdiction
        United States 4
        World 4
Date
2024 2
2021 1
Before 2020 5
IPC Class
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids 5
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical 4
C12N 15/11 - DNA or RNA fragmentsModified forms thereof 4
B82Y 10/00 - Nanotechnology for information processing, storage or transmission, e.g. quantum computing or single electron logic 3
C07H 21/00 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids 3
See more
Status
Pending 2
Registered / In Force 6
Found results for  patents

1.

ROTATIONALLY SEQUESTERED TRANSLATORS

      
Application Number 18753979
Status Pending
Filing Date 2024-06-25
First Publication Date 2024-10-17
Owner Emerald Therapeutics, Inc. (USA)
Inventor
  • Kleinbaum, Daniel J.
  • Frezza, Brian M.
  • Bond, Brad
  • Leung, Jonathan
  • Fraser, George W.

Abstract

Provided are nucleic acid translators capable of carrying out logic operations with improved efficiency, maximized output and reduced off-target effects, in particular in a biological system. Methods of using these translators to transduce signal are also provided.

IPC Classes  ?

  • C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
  • B82Y 10/00 - Nanotechnology for information processing, storage or transmission, e.g. quantum computing or single electron logic
  • C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
  • C12N 15/11 - DNA or RNA fragmentsModified forms thereof
  • C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
  • G06N 3/00 - Computing arrangements based on biological models
  • G06N 3/123 - DNA computing

2.

PREPARATION OF OLIGO CONJUGATES

      
Application Number 18504925
Status Pending
Filing Date 2023-11-08
First Publication Date 2024-08-01
Owner Emerald Therapeutics, Inc. (USA)
Inventor
  • Frezza, Brian M.
  • Webster, Courtney E.
  • Kleinbaum, Daniel J.

Abstract

Conjugated molecules are prepared that comprise a predetermined number of oligo conjugation components. The conjugated molecules also may comprise one or more detectable labels. Preparation of these molecules can be implemented according to an asymmetric or a symmetric conjugation strategy.

IPC Classes  ?

  • C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
  • A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
  • C07H 21/00 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
  • C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof

3.

Rotationally sequestered translators

      
Application Number 17107699
Grant Number 12054713
Status In Force
Filing Date 2020-11-30
First Publication Date 2021-04-08
Grant Date 2024-08-06
Owner Emerald Therapeutics, Inc. (USA)
Inventor
  • Kleinbaum, Daniel J.
  • Frezza, Brian M.
  • Bond, Brad
  • Leung, Jonathan
  • Fraser, George W.

Abstract

Provided are nucleic acid translators capable of carrying out logic operations with improved efficiency, maximized output and reduced off-target effects, in particular in a biological system. Methods of using these translators to transduce signal are also provided.

IPC Classes  ?

  • C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
  • B82Y 10/00 - Nanotechnology for information processing, storage or transmission, e.g. quantum computing or single electron logic
  • C12N 15/11 - DNA or RNA fragmentsModified forms thereof
  • C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
  • C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
  • G06N 3/00 - Computing arrangements based on biological models
  • G06N 3/123 - DNA computing

4.

Rotationally sequestered translators

      
Application Number 15470754
Grant Number 10479994
Status In Force
Filing Date 2017-03-27
First Publication Date 2017-07-13
Grant Date 2019-11-19
Owner Emerald Therapeutics, Inc. (USA)
Inventor
  • Kleinbaum, Daniel J.
  • Frezza, Brian M.
  • Bond, Brad
  • Leung, Jonathan
  • Fraser, George W.

Abstract

Provided are nucleic acid translators capable of carrying out logic operations with improved efficiency, maximized output and reduced off-target effects, in particular in a biological system. Methods of using these translators to transduce signal are also provided.

IPC Classes  ?

  • C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
  • C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
  • C12N 15/11 - DNA or RNA fragmentsModified forms thereof
  • C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
  • G06N 3/00 - Computing arrangements based on biological models
  • G06N 3/12 - Computing arrangements based on biological models using genetic models
  • B82Y 10/00 - Nanotechnology for information processing, storage or transmission, e.g. quantum computing or single electron logic

5.

PREPARATION OF OLIGO CONJUGATES

      
Application Number US2014021148
Publication Number 2014/138373
Status In Force
Filing Date 2014-03-06
Publication Date 2014-09-12
Owner EMERALD THERAPEUTICS, INC. (USA)
Inventor
  • Frezza, Brian, M.
  • Webster, Courtney, E.
  • Kleinbaum, Daniel, J.

Abstract

Conjugated molecules are prepared that comprise a predetermined number of oligo conjugation components. The conjugated molecules also may comprise one or more detectable labels. Preparation of these molecules can be implemented according to an asymmetric or a symmetric conjugation strategy.

IPC Classes  ?

  • C07H 21/00 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
  • C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides

6.

ROTATIONALLY SEQUESTERED TRANSLATORS

      
Application Number US2014011782
Publication Number 2014/113531
Status In Force
Filing Date 2014-01-16
Publication Date 2014-07-24
Owner EMERALD THERAPEUTICS, INC. (USA)
Inventor
  • Kleinbaum, Daniel, J.
  • Frezza, Brian, M.
  • Bond, Brad
  • Leung, Jonathan
  • Fraser, George, W.

Abstract

Provided are nucleic acid translators capable of carrying out logic operations with improved efficiency, maximized output and reduced off-target effects, in particular in a biological system. Methods of using these translators to transduce signal are also provided.

IPC Classes  ?

  • C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
  • C07H 21/00 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
  • C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
  • G06F 19/20 - for hybridisation or gene expression, e.g. microarrays, sequencing by hybridisation, normalisation, profiling, noise correction models, expression ratio estimation, probe design or probe optimisation

7.

POLYNUCLEOTIDE PROBE DESIGN

      
Application Number US2013045319
Publication Number 2013/188491
Status In Force
Filing Date 2013-06-12
Publication Date 2013-12-19
Owner EMERALD THERAPEUTICS, INC. (USA)
Inventor
  • Frezza, Brian, M.
  • Bond, Bradly, M.
  • Melton, Collin, A.
  • Hofler, Catherine, L.
  • Kleinbaum, Daniel, J.

Abstract

An approach to designing a polynucleotide probe to hybridize selectively to a target polynucleotide sequence involves calculating the final concentration of the intended binding product between a candidate probe and the target sequence. The calculation takes into consideration the binding reaction between the candidate probe and the target fragment on the target sequence, as well as various other binding reactions, involving either the probe or the target fragment, that interfere with the intended binding reaction. In contrast to the conventional technology, which attempts to determine the entire structure of the target polynucleotide, this approach only needs to determine the binding dynamics that impact on the intended probe-target fragment binding. The approach does not require determination of the structure of the involved sequences.

IPC Classes  ?

  • C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
  • C12N 15/11 - DNA or RNA fragmentsModified forms thereof
  • G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor

8.

SYSTEM AND METHOD FOR PROPAGATING INFORMATION USING MODIFIED NUCLEIC ACIDS

      
Application Number US2011029947
Publication Number 2011/149584
Status In Force
Filing Date 2011-03-25
Publication Date 2011-12-01
Owner EMERALD THERAPEUTICS, INC. (USA)
Inventor Kleinbaum, Daniel, J.

Abstract

A method for improving a nucleic acid-based molecular computing system includes (A) identifying a computing system comprised of (i) a nucleic acid structure that includes an incompletely base-paired duplex domain, (ii) at least one polynucleotide displacement molecule that can bind with the nucleic acid structure under hybridizing conditions, such that the nucleic acid structure undergoes a transition in energy state due to a branch migration reaction involving the duplex domain, and (iii) a clashing polynucleotide molecule that competes with the polynucleotide displacement molecule for binding the nucleic acid structure under the hybridizing conditions but that cannot produce a branch migration reaction involving the duplex domain; then (B) reconfiguring at least one of the displacement molecule and the nucleic acid structure, respectively, to incorporate a chemical modification relative to a first reference molecule that comprises natural nucleosides and has the same sequence content as the displacement molecule or the nucleic acid structure, as the case may be, wherein the modification causes binding of the displacement molecule and the nucleic acid structure to have a hybridization free energy, differing from that of a first reference binding between the displacement molecule or the nucleic acid structure and the first reference molecule, such that the branch migration reaction is facilitated relative to the first reference binding; and/or (C) reconfiguring at least one of the clashing molecule and the nucleic acid structure, respectively, to incorporate a chemical modification relative to a second reference molecule that comprises natural nucleosides and has the same sequence content as the clashing molecule or the nucleic acid structure, as the case may be. The modification effected via such reconfiguring causes binding of the clashing molecule and the nucleic acid structure to have a hybridization free energy, differing from that of a second reference binding between the clashing molecule or the nucleic acid structure and the second reference molecule, such that binding of the clashing molecule is impeded relative to the second reference binding.

IPC Classes  ?

  • G06F 19/10 - Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology (in silico methods of screening virtual chemical libraries C40B 30/02;in silico or mathematical methods of creating virtual chemical libraries C40B 50/02)